MARKET

SPHRF

SPHRF

Starpharma Holdings Ltd
OTCMQB
0.240
NaN%
Closed 09:30 02/12 EST
OPEN
--
PREV CLOSE
0.240
HIGH
--
LOW
--
VOLUME
2.50K
TURNOVER
843
52 WEEK HIGH
0.240
52 WEEK LOW
0.056
MARKET CAP
100.78M
P/E (TTM)
-15.2866
1D
5D
1M
3M
1Y
5Y
1D
Starpharma Ramps Up DEP® Partnerships and Radiopharma Pipeline as Viraleze™ Sales Surge
TipRanks · 01/29 02:27
Starpharma Seeks ASX Quotation for 1.69 Million New Ordinary Shares
TipRanks · 01/07 02:18
Starpharma Announces Lapse of 381,810 Performance Rights
TipRanks · 01/07 02:17
Starpharma CEO Receives New Performance Rights
TipRanks · 12/17/2025 03:28
Starpharma Issues Unquoted Securities to Boost Employee Incentives
TipRanks · 12/17/2025 03:18
Starpharma Announces Successful 2025 AGM Results
TipRanks · 11/14/2025 05:30
Starpharma Announces Strategic Partnerships and Growth at AGM
TipRanks · 11/14/2025 03:08
Starpharma Secures Key Partnerships and Advances Strategic Initiatives in Q1 FY26
TipRanks · 10/28/2025 00:09
More
About SPHRF
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.

Webull offers Starpharma Holdings Ltd stock information, including OTCMQB: SPHRF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPHRF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPHRF stock methods without spending real money on the virtual paper trading platform.